Avalglucosidase alfa (GZ402666)
ApprovedActive 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II
Conditions
Glycogen Storage Disease Type II
Trial Timeline
Jul 11, 2022 → Sep 30, 2026
NCT ID
NCT05164055About Avalglucosidase alfa (GZ402666)
Avalglucosidase alfa (GZ402666) is a approved stage product being developed by Sanofi for Glycogen Storage Disease Type II. The current trial status is active. This product is registered under clinical trial identifier NCT05164055. Target conditions include Glycogen Storage Disease Type II.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05164055 | Approved | Active |
Competing Products
20 competing products in Glycogen Storage Disease Type II